Program
insulin degludec
Also written as “insulin degludec/insulin aspart”, “insulin degludec/liraglutide” and “Insulin degludec”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus, Type 1 · Diabetes Mellitus, led by 5 companies.
Drug pageInsulin degludec: every studyMany companies study it; this page follows only the 105 they lead. All 128 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novo Nordiskits history only | 1000 open or running | phase 4since Sep 21, 2018 | Jan 30, 2008 | none ahead |
| Tonghua Dongbao Pharmaceuticalits history only | 22 open or running | phase 3since Aug 14, 2024 | Jun 2, 2024 | none ahead |
| Gan & Lee Pharmaceuticalsits history only | 11 open or running | phase 1since Aug 18, 2025 | Aug 18, 2025 | none ahead |
| Sino Biopharmaceuticalits history only | 11 open or running | phase 3since Jul 5, 2021 | Jul 5, 2021 | none ahead |
| Sunshine Lake Pharma | 10 open or running | phase 3since Mar 6, 2023 | Mar 6, 2023 | none ahead |
Also a collaborator on its studies: Profil Institut für Stoffwechselforschung.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Sunshine Lake Pharma only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 6, 2023First study: phase 3 study in Diabetes MellitusFirst studyNCT05802862 · 414 enrolled · China
TargetBeta
“Insulin receptor agonist”ChEMBL 37, by rule
Other programs on INSR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Insulin Glarginerule | Sanofi | phase 4 | 190 |
| Insulin Aspartrule | Novo Nordisk | phase 4 | 146 |
| Insulinrule | Pfizer | phase 4 | 50 |
| insulin glulisinerule | Sanofi | phase 4 | 43 |
| insulin icodecrule | Novo Nordisk | phase 4 | 30 |
| linsitinibrule | Astellas Pharma | phase 3 | 13 |
| LY3938577 | Eli Lilly | phase 2 | 3 |
Studies
The one study Sunshine Lake Pharma leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05802862Diabetes Mellitus · China | 3 | Completed | Aug 16, 2024 | 414 |
How it is read
Names in the registry
- “insulin degludec”, 73 entries
- “insulin degludec/insulin aspart”, 35 entries
- “insulin degludec/liraglutide”, 17 entries
- “Insulin degludec”, 4 entries
- “Insulin degludec/liraglutide”, 3 entries
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 58 studies
- Diabetes Mellitus, Type 1, 31 studies
- Diabetes Mellitus, 16 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.